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Abstract
Thrombolysis and primary angioplasty are both recommended reperfusion strategies for
elderly patients presenting with myocardial infarction (MI). Primary angioplasty is most
beneficial in high-risk patients. While the elderly have a high absolute risk of dying or
developing complications after MI, they also have an increased risk of intracranial
haemorrhage if they are given thrombolytic therapy. It could therefore be reasonably argued
that primary angioplasty is the reperfusion strategy of choice in the elderly. However, primary
angioplasty has not been shown to have a greater relative benefit than thrombolytic therapy in
the elderly. Recent data from the Fibrinolytic Therapy Trialists’ (FTT) Collaborative Group
show that thrombolytic therapy significantly reduces mortality compared with control
treatment in patients over 75 years of age presenting within 12 h of symptom onset, with ST-
segment elevation or bundle branch block. Future advances in adjunctive therapies may
improve myocyte perfusion and hence the outcomes achieved by both invasive and
noninvasive reperfusion strategies. Better thrombolytic regimens incorporating adjunctive
agents such as bivalirudin may reduce the risk of intracranial haemorrhage. Few hospitals can
provide a 24-h primary angioplasty service with door-to-balloon times consistently less than
90 min, and thrombolytic therapy is therefore a far more practical option in most instances.
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Introduction
Primary angioplasty and thrombolytic therapy have both
been recommended as appropriate reperfusion thera-
pies for patients presenting with either ST-segment ele-
vation or new-onset left bundle branch block, within
12 h of the onset of ischaemic symptoms [1]. Certain
caveats apply to the recommendations for primary
angioplasty, including the prior experience of the opera-
tor (who must perform at least 75 procedures per year)
and the throughput of the centre (which must perform at
least 200 procedures per year). The procedure must
also be performed in a timely fashion, ie balloon dilation
must occur within 60 to 90 min of the diagnosis of
acute MI.http://cvm.controlled-trials.com/content/1/3/150
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The evidence for thrombolytic therapy is based on ran-
domised comparisons with placebo or control treatment in
over 100,000 patients [2]. The evidence for primary angio-
plasty is based on comparisons with thrombolytic therapy
in a total of 2745 patients, of whom 1348 underwent
primary angioplasty. The FTT collaborative overview of all
large thrombolytic trials included data from 5788 patients
aged ³75 years, whereas the recent systematic overview
of primary angioplasty trials included data from only 199
patients aged ³75 years, 149 of whom underwent primary
angioplasty [3].
The FTT overview did not specifically report the outcomes
of elderly patients presenting with ST-segment elevation
or bundle branch block within 12 h of symptom onset, and
did not include data on gender or infarct site. It did,
however, include all patients randomised up to 24 h after
symptom onset, regardless of electrocardiographic find-
ings (eg normal electrocardiograms, T-wave inversion, ST-
segment depression, etc). In the 5788 patients ³75 years
of age presenting with any electrocardiographic changes
within 24 h of symptom onset, thrombolytic therapy
reduced mortality nonsignificantly from 25.3% to 24.3%
(95% confidence interval –16 to 36).
New thrombolytic data
New data from the FTT Collaborative Group show that in
patients over 75 presenting with ST-segment elevation or
bundle branch block within 12 h of symptom onset, throm-
bolytic therapy reduced the mortality rate significantly by
15% (from 29.4% with control treatment to 26.0%,
P = 0.03). This represents 34 lives saved per 1000 patients
treated, twice the benefit seen in patients aged <55 years
(16 lives saved per 1000 treated) (personal communication
from the FTT Secretariat, dated 4 August 2000).
These results can be generalised to community hospitals
as the bulk of the data in the FTT overview came from the
Second International Study of Infarct Survival (ISIS-2) and
Gruppo Italiano per lo Studio della Streptochinasi nell’In-
farto Miocardico (GISSI-1) trials, which were conducted
predominantly in non-academic centres. Unlike primary
angioplasty, thrombolytic therapy requires no specialised
skills. In a study of 516 United States (US) hospitals, there
was no significant association between the volume of
thrombolytic treatments given and in-hospital mortality [4],
whereas the in-hospital mortality rates associated with
primary angioplasty were 28% lower in high-volume
centres (>33 procedures/year) than in low-volume
centres (5 to 11 procedures/year).
Registry studies
Several registry studies [5,6] have recently concluded that
thrombolytic therapy worsens outcomes in the elderly. In a
US Medicare observational study, the 30-day mortality
rates among 7864 patients aged between 76 and 86
years presenting within 4 h of symptom onset were 15.4%
with thrombolytic therapy and 18% with control treatment
(P = 0.003). The authors concluded that thrombolytic
therapy was ‘unlikely to confer survival benefit and may
have significant disadvantage’ [5]. It should be noted,
however, that a large proportion of the patients given
thrombolytic therapy had contraindications, for example
12% had a systolic blood pressure of >180 mmHg, and
18% had a recent history of trauma, peptic ulcer or inter-
nal bleeding.
The Cooperative Cardiovascular Project [6], which
studied 16,305 patients considered ‘ideal’ for reperfusion
therapy, reported that 30-day mortality rates were reduced
by primary angioplasty, but not by thrombolytic therapy. At
1 year, however, both treatment modalities were associ-
ated with lower mortality rates than control treatment
(odds ratios for mortality 0.85 [95% confidence interval
0.77 to 0.94] with thrombolytic therapy and 0.63 [95%
confidence interval 0.49 to 0.81] with primary angioplasty,
after adjustment for baseline characteristics). Patients who
received thrombolytic therapy within 30 min had lower
mortality rates at both 30 days and 1 year than those who
received it later. In patients over 65, the mean time to
thrombolytic therapy was 62 ± 48 min and the mean time
to primary angioplasty was 131 ± 60 min. Only 42% of eli-
gible patients with no absolute contraindications against
thrombolytic therapy received reperfusion therapy (4.2%
underwent primary angioplasty) [6].
Although adjustments were made for known variables in
both of these studies, observational studies can some-
times be confounded by the influence of unforeseen
factors. For this reason, randomised trial data are usually
considered more reliable because randomisation helps to
ensure that unforeseen factors are balanced between the
different treatment groups. It is inappropriate to rely upon
registry data as a basis for clinical management, as illus-
trated by various large registry studies that have subse-
quently been shown to be wrong [7,8].
In most instances the relative benefits of treatment are
similar across different risk groups, unless there is an a
priori reason why a particular subgroup should differ in its
response to treatment. Thus, patients at higher risk will gain
a greater absolute benefit from treatment. Following MI the
elderly have a much higher mortality rate and a higher inci-
dence of complications such as heart failure and cardio-
genic shock. They are also more prone to the haemorrhagic
complications of thrombolytic therapy, such as intracranial
haemorrhage, and one would therefore expect primary
angioplasty to have its greatest benefit in the elderly.
Angioplasty in the elderly
There are, however, few data specifically concerning
primary angioplasty in the elderly. In the Primary Angio-Current Controlled Trials in Cardiovascular Medicine    Vol 1 No 3 White
plasty in Myocardial Infarction (PAMI) study, which com-
pared angioplasty with the older 3-h tissue plasminogen
activator (TPA) infusion regimen, the greatest benefit was
observed in patients over 65. There was no significant
reduction in the combined endpoint of death/MI in
patients under 65 (0.8% mortality in both groups), but
there was a marked reduction in the same endpoint in
patients ³65 (death/MI was 8.6% with angioplasty versus
20.0% with TPA, P = 0.048) [9]. In the Global Use of
Strategies to Open Occluded Coronary Arteries
(GUSTO)-IIB trial, the largest randomised trial comparing
angioplasty with thrombolytic therapy, 1138 patients were
randomised to receive either accelerated TPA or primary
angioplasty. Although primary angioplasty resulted in
better 30-day outcomes (death/MI/stroke occurred in
9.6% versus 13.7% with TPA, P = 0.03), there was no
significant difference in death/MI at 6 months (13.3%
versus 15.0%, respectively, odds ratio 0.87 [95% confi-
dence interval 0.62 to 1.23]). While the absolute benefit
of angioplasty was greater with each decade of life, the
relative benefit was no greater in older than in younger
patients [10]. Although the numbers were small (n = 90)
there was no difference in mortality for patients ³80 years
(27.3% with angioplasty versus 26.7% with TPA). Like-
wise, a recent systematic overview of all trials comparing
primary angioplasty with thrombolytic therapy reported
that there was no difference in the relative benefit in the
elderly, although the absolute benefit was greater [3].
Why aren’t the advantages of angioplasty over thrombolytic
therapy greater in the elderly than in younger patients? One
reason is that elderly patients tend to delay longer before
presenting for treatment, thus reducing the window of
opportunity for myocardial salvage. This is particularly disad-
vantageous in patients treated with primary angioplasty,
who already face a longer wait for reperfusion once they
arrive at hospital, compared with those treated with throm-
bolytic therapy, which can be initiated sooner [11]. The
elderly also tend to have more severe coronary stenoses
and greater impairment of Thrombolysis in Myocardial
Infarction (TIMI) grade 3 flow at baseline. In GUSTO-IIB, for
instance, TIMI grade 3 flow was present in 19% of patients
aged <40 versus 6% of those aged 70 to 79 [10].
There is evidence that thrombolytic therapy lyses coronary
artery thrombi just as well in the elderly as it does in
younger patients [12]. In the GUSTO-I angiographic sub-
study, univariate and multivariate analysis showed that age
was not a predictor of TIMI flow grades at 90 min, with
similar proportions of patients under and over the age of
75 achieving TIMI grade 3 flow (38% versus 37%) [13].
Although the elderly are more prone to bleeding (particu-
larly intracranial haemorrhage) following thrombolytic
therapy [14], most patients suffering intracranial haemor-
rhage die (60% in GUSTO-I) rather than survive with a
disability (20% in GUSTO-I), and so the benefit:risk ratio
of thrombolytic therapy is largely already accounted for in
the mortality statistics.
The recent systematic overview of all trials comparing
primary angioplasty with thrombolytic therapy [3] showed
that the mortality benefits were maintained at 6 months, but
with borderline statistical significance (P = 0.04). Some of
the trials had missing data, and if one extra death had
occurred in the angioplasty limb of one of these trials, or if
two studies had reported equal outcomes, there would
have been no significant overall mortality advantage associ-
ated with primary angioplasty. In this overview, there was a
trend showing that longer door-to-balloon times tended to
be associated with lesser benefits of primary angioplasty. 
In the recent Stent-PAMI study, the mean door-to-balloon
time was 112 min [15]. Some researchers have suggested
that the time to treatment may be less important with
primary angioplasty than with thrombolytic therapy [16].
The scientific rationale for this is uncertain as myocardial
salvage is clearly time-dependent, and patency of the
infarct-related artery has other long-term advantages that
are independent of salvage, such as decreased left ventric-
ular remodelling, improved electrical stability, and the
capacity for collateral supply to other coronary territories in
the event of reinfarction [17]. Although thrombolytic
therapy is less effective at lysing old clots [18], patency
does improve with time. In GUSTO-I, for instance, streptok-
inase achieved patency (TIMI grade 2 or 3) in 57% of
patients by 90 min and 73% by 180 min, while accelerated
TPA achieved patency in 76% by 180 min. In the Second
US National Registry of Myocardial Infarction, 27,080
patients were treated with primary angioplasty between
June 1994 and March 1998, and it was found that the mor-
tality rate was significantly related to the door-to-balloon
time (median 116 min) [19]. The adjusted mortality rates
were 41% higher in patients with door-balloon times of
>2 h and 62% higher in those with door-to-balloon times
of >3 h (P < 0.001). It should be noted that the timing of
angioplasty was not randomised in these studies.
The quest for more effective pharmacological reperfusion
strategies must be balanced against the risk of increasing
intracranial haemorrhage rates [20]. The percentage of
patients suffering intracranial haemorrhage has risen with
the introduction of the newer thrombolytic agents, partly
because more elderly patients are now being included in
clinical trials, and possibly also because the ability to
detect haemorrhagic complications has improved.
However, the increase in intracranial haemorrhage cannot
be entirely explained by changing demographics [21].
Tenecteplase is a new, relatively fibrin-specific bolus
thrombolytic agent. In the Second Assessment of the
Safety and Efficacy of a New Thrombolytic (ASSENT-2)
trial [22], the rates of major bleeding (ie life-threatening,
resulting in death or requiring transfusion) in the over-75age group were 8.12% with tenecteplase and 11.62%
with TPA. The rates of intracranial haemorrhage in the
same age group were 1.72% and 2.62%, respectively.
These results suggest that tenecteplase may be particu-
larly suitable for use in the elderly, as may newer throm-
bolytic regimens incorporating either a half-dose
thrombolytic plus a IIb/IIIa inhibitor or a full-dose throm-
bolytic plus the direct thrombin inhibitor, bivalirudin, which
have been shown to cause less bleeding than unfraction-
ated heparin [23].
Angioplasty with stenting has been shown to achieve TIMI
grade 3 flow in a very high proportion of patients, for
example 86% in Stent-PAMI [15]. However, this figure
does not apply to all patients. In Stent-PAMI the trial reg-
istry showed that of the 1458 patients with acute MI who
were screened, only 900 (62%) were randomised. Of
those not randomised, 38% did not undergo angioplasty.
The reasons why angioplasty is sometimes not performed
include poor vascular access, renal failure and other
comorbid conditions. If a ‘rule of ninety-fives’ is applied to
all patients with acute MI who are eligible for reperfusion
(ie 95% of patients are eligible for angioplasty ± stenting,
95% of these procedures are successful, and 95% of
patients whose procedures are successful achieve TIMI
grade 3 flow), then the actual incidence of TIMI grade 3
flow for all comers is 86% (ie 95% × 95% × 95%). This
incidence of TIMI grade 3 flow is no better than that
achieved with half-dose TPA plus abciximab in the TIMI-14
trial [24]. It is also important to remember that in the real
world, primary angioplasty takes considerably longer to
perform than thrombolysis. The interventionist performing
the procedure may well be less experienced than those
participating in clinical trials, which tend to be conducted
in centres of excellence. The patency rates achieved by
primary angioplasty in the real world may therefore be
nearer those seen with thrombolytic therapy than those
achieved under optimal clinical trial conditions [11]. It is
likely that advances in adjunctive therapies will enhance
the reperfusion rates achieved by both approaches, and
hence patient outcomes should also improve.
Conclusion
Primary angioplasty has its greatest benefit in high-risk
patients and in the elderly, for whom thrombolysis carries
an increased risk of stroke (particularly haemorrhagic
stroke). Although there is potential to develop chest pain
units where patients with acute MI could be triaged for
transfer to centres of excellence with expertise in angio-
plasty, the costs and logistical difficulties of such an
approach would be considerable. Only about 25% of hos-
pitals in the US have the capacity to perform angioplasty,
and so it is unlikely that this procedure will be readily avail-
able to the majority of patients presenting with acute MI in
the near future. Prompt administration of a thrombolytic
regimen, with facilitated angioplasty reserved for patients
identified as high-risk (such as the elderly and patients
with evidence of reperfusion failure), is likely to result in
the greatest good for the greatest number of patients.
Regardless of the reperfusion strategy used, event rates in
the elderly remain high, and so further research is needed
to develop better treatments. Meanwhile, it is vital that as
many patients as possible receive reperfusion therapy as
soon as possible by whichever means is available.
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